The Peter Attia Drive - December 10, 2018


#32 - Siddhartha Mukherjee, M.D., Ph.D.: new frontiers in cancer therapy, medicine, and the writing process

Topics
Hosted by
Mentioned
#31 - Navdeep Chandel, Ph.D.: metabolism, mitochondria, and metformin in health and disease #33 - Rudy Leibel, M.D.: Finding the obesity gene and discovering leptin

Episode Stats


Length

1 hour and 5 minutes

Words per minute

197.5

Word count

12,880

Sentence count

898

Harmful content

Misogyny

3

sentences flagged

Toxicity

1

sentences flagged

Hate speech

4

sentences flagged


Summary

Summaries generated with gmurro/bart-large-finetuned-filtered-spotify-podcast-summ .

Sid Mukherjee is a Pulitzer Prize-winning writer and a remarkable physician and scientist. In fact, probably there s nobody I know that combines those three things as efficaciously as Sid does. His biography reads like I'm making it up. He studied biology at Stanford, then became a Rhodes Scholar, went to Oxford, earned his PhD in immunology, returned to the United States to earn his MD at Harvard, etc. etc. Fast forward to today, Sid is an associate professor of medicine in the Division of Hematology and Oncology at Columbia University, which is where we met to do this interview. He has published consistently in both the New Yorker and the New York Times, which in and of itself is quite a distinction. And of course, he s published in the New England Journal of Medicine, Nature, and a whole host of other medical journals.

Transcript

Transcript generated with Whisper (turbo).
Misogyny classifications generated with MilaNLProc/bert-base-uncased-ear-misogyny .
Toxicity classifications generated with s-nlp/roberta_toxicity_classifier .
Hate speech classifications generated with facebook/roberta-hate-speech-dynabench-r4-target .
Topics generated with Qwen2.5-3B-Instruct.
Hosts, guests, and mentioned names generated with spaCy (en_core_web_sm), reconciled against Wikidata.
00:00:00 Hey everyone, welcome to the Peter Atiyah Drive. I'm your host, Peter Atiyah.
00:00:10 The Drive is a result of my hunger for optimizing performance, health, longevity, critical thinking,
00:00:15 along with a few other obsessions along the way. I've spent the last several years working with
00:00:19 some of the most successful, top-performing individuals in the world, and this podcast
00:00:23 is my attempt to synthesize what I've learned along the way to help you live a higher quality,
00:00:28 more fulfilling life. If you enjoy this podcast, you can find more information on today's episode
00:00:33 and other topics at peteratiyahmd.com.
00:00:41 Hey everybody, welcome to this week's episode of The Drive. My guest this week is Sid Mukherjee,
00:00:48 who is a remarkable writer, in fact a Pulitzer Prize-winning writer, and a remarkable physician
00:00:54 and scientist. In fact, probably there's nobody I know that combines those three things
00:00:59 as efficaciously as Sid does. His biography reads like I'm making it up. He studied biology at
00:01:06 Stanford. He then became a Rhodes Scholar, went to Oxford, earned his PhD in immunology, returned to
00:01:12 the United States to earn his MD at Harvard, etc., etc., etc. Fast forward to today, he is an associate
00:01:18 professor of medicine in the Division of Hematology and Oncology at Columbia University,
00:01:22 which is where we met to do this interview. He has published also and continues to publish
00:01:27 consistently in both the New Yorker and the New York Times, which in and of itself is quite a
00:01:32 distinction as I would learn. Typically one is on either side of those, but not both. And of course
00:01:37 he's published in the New England Journal of Medicine, Nature, in addition to a whole host of
00:01:41 other medical journals. I met Sid probably five years ago at a dinner that was set up by Lou Cantley,
00:01:47 someone I'll be interviewing very shortly, who will be a guest obviously soon. And while I remember
00:01:52 that dinner very well, I was surprised to learn that it left such an impression on Sid. And he
00:01:57 described it as something to the effect of one of the most interesting and perhaps important
00:02:00 scientific collaborations in his life that stemmed from it. As we kind of jotted out a napkin experiment
00:02:06 that went on to become a paper that was published by a group led by Lou and Sid. And that paper was
00:02:13 published this past summer. And we talk about that in detail. That paper involved the use of ketogenic
00:02:18 diets in combination with a class of drugs called PI3 kinase inhibitors. We're going to go into great
00:02:25 detail on that. So I obviously don't want to repeat any of that stuff here. But I think for those of you
00:02:29 that are interested in cancer, you're obviously going to find this episode very interesting. But
00:02:33 the other thing with Sid is it doesn't matter if you have no interest in cancer. I think you'll find
00:02:38 this discussion interesting because Sid has a way of making everything interesting. And that to me
00:02:42 is part of Sid's gift. When I got his book, The Gene in the summer of 2016, when it came out,
00:02:48 it's one of probably only six books in my life that I was not able to stop reading from the moment I
00:02:56 started. So it was one of those things where everything else I was doing had to be put aside
00:03:01 for a few days until I could finish that book. That's just the way Sid writes. And that's also the
00:03:07 way he speaks. He is a unique human being. And I think that will come across in this interview.
00:03:13 The other thing that was a total pleasant surprise to me was in doing the research for this podcast
00:03:17 was coming across a book that I was ashamed to admit I didn't even know he'd written called
00:03:22 The Laws of Medicine, or I believe it's called The Three Laws of Medicine. And we talk about these
00:03:28 three laws. And rather than even stating them now, I just think it's worth, this podcast is worth the
00:03:33 price of admission just on the basis of understanding those three laws. So with that, I hope you will
00:03:38 welcome Sid to the show. And I do want to just remind folks to please sign up for the email list.
00:03:44 I've been putting a lot of effort into those emails every Sunday morning, they go out. And I hope that
00:03:49 they're at least worth some value. I think they are. And I like to be able to kind of share things
00:03:53 with folks that I'm reading or seeing along the way. And they don't always have to do with longevity.
00:03:57 Keep in mind, one of the things that I think takes up more actual time than anything else with respect
00:04:03 to this podcast is putting together the show notes. So Bob and Travis work really hard on those. And
00:04:09 the feedback we've been getting is incredible. People keep saying, my God, how do you make these
00:04:13 things? And the short answer is, I don't. I don't do any of it. But Bob and Travis do, especially
00:04:17 Travis. And I think that if you spend a few minutes looking at that stuff, especially if you find some
00:04:22 of the content challenging. And when we get into technical terms, which we do on some of the podcasts,
00:04:26 you're pretty much going to find everything in the show notes. Lastly, if you're enjoying this,
00:04:30 it would be an honor if you would head on over to Apple Podcast Reviews and leave us a review,
00:04:34 especially if it's a positive one. But we'll take a negative one too, as long as you can be
00:04:37 constructive in your feedback. So without further delay, here is my guest today, Sid Mukherjee.
00:04:46 Hey, Sid. Thanks for making time.
00:04:49 My pleasure. Thanks for being here.
00:04:50 Yeah, I don't get up to this part of the city very often. It's a bit of a hike.
00:04:55 Well, it's a massive medical school and it's hard to imagine it anywhere else except for
00:04:59 uptown in this way. We go right all the way to the river.
00:05:03 It's amazing. And the last time I was up here was to see another one of your colleagues on the
00:05:06 other side of the street, Rudy Leibel, who's a good friend. And I used to be up here a lot more
00:05:10 often. So it was nice to come back. Most of our podcasts go really, really long. This one,
00:05:15 I don't think we have that luxury of time. So I kind of want to get right into things. But
00:05:18 before we do, I certainly think for the listener who doesn't know you well, your background,
00:05:22 which I'll allude to a lot in the introduction. So we don't spend too much time on it. But you
00:05:26 grew up in India, came to the US. Did you do college here?
00:05:30 I went to college at Stanford. Yeah.
00:05:32 Oh, that's right. You went to undergrad at Stanford. Okay. Then medical school at Harvard.
00:05:35 Actually, then in the middle, I was away for three years. I did...
00:05:39 You did a Rhodes Scholarship. Yeah.
00:05:40 Or you're a Rhodes Scholar. Yeah.
00:05:41 I was a Rhodes Scholar. And that's where I got my PhD. And my PhD is in immunology,
00:05:44 which is a subject that I left behind, went to medical school at Harvard Medical School,
00:05:51 then did my fellowship, my internship, my residency at Mass General Hospital,
00:05:57 fellowship at the Dana-Farber Cancer Institute, and then started my own lab and clinical practice
00:06:02 at Columbia University. And have come back to immunology in a strange, widening circle of a way.
00:06:10 Yeah. The first time we met was a dinner that Lou Cantley had planned for us. This is about three
00:06:15 or four years ago. And I remember at the time, the topic that Lou is passionate about that I'm
00:06:20 passionate about was sort of metabolism of cancer. And at the time, it wasn't something that seemed
00:06:25 as interesting to you as it is today. And I know today I want to talk so much more about that because
00:06:28 the work you guys have done in the last few years is in many ways what I think is the most
00:06:32 interesting stuff to talk about. It was also a tough dinner because you don't eat most things.
00:06:36 It's hard to have dinner with someone when half the menu is off the menu. So anyway,
00:06:42 we somehow managed and scraped by and it was a wonderful evening. It actually led to,
00:06:47 what was that, five years ago?
00:06:48 Yeah.
00:06:49 Led to one of the most interesting and perhaps important scientific collaborations in my life.
00:06:54 With Lou.
00:06:54 With Lou. But it was that dinner which we kind of hammered. It was in a Japanese restaurant on the
00:06:59 Upper East Side in a tiny little place.
00:07:01 You remember? That's exactly, I know exactly where we were.
00:07:03 And exactly where it was. Well, because we wrote on a, you know, it was a little bit like one of
00:07:07 these napkin experiments where you write on a napkin an idea and that idea takes five years to come
00:07:13 alive. This thing that was sketched on a napkin that evening and is now leading to a actually kind
00:07:18 of a massive clinical trial across multiple sites. Very energetic teams coming into all of this out of
00:07:25 that little napkin on a Japanese restaurant.
00:07:27 Yeah. That was a really fun night. Prior to that, I had read The Emperor of All Maladies. I don't
00:07:32 think The Gene was out yet.
00:07:34 The Gene was not out yet.
00:07:35 I want to spend just a couple minutes on The Emperor of All Maladies because if there's anybody 0.98
00:07:38 listening to this who hasn't read it, you won the Pulitzer Prize for that book, I believe.
00:07:41 I did, yes.
00:07:41 Yeah. So it's a must read. Having myself studied in oncology, there was so much that I learned.
00:07:48 You know, I trained at Hopkins, which is, you know, so we're in the Halstead school of where
00:07:52 the mastectomy was created, where many of these things were created. But to really understand the
00:07:56 history of Bernard Fisher's role in the mastectomy, it's just an unbelievable story. My only criticism
00:08:02 was at the time quite a depressing story. I mean, I'm not saying that to be critical. It's less a
00:08:09 criticism of youth in the field.
00:08:10 No, no. It was, to me, actually, interestingly, people often bring this idea up. For me, it was
00:08:15 actually, it's far from a depressing story. It's just the opposite. In fact, if we don't contend with
00:08:21 the question of how, I mean, The Emperor of All Maladies, just for people who don't know, is a
00:08:25 history of cancer, starting from its first description in Egypt, right down to my own patients,
00:08:32 thousands of years of a journey against a disease that seems to morph and change over time.
00:08:38 And every time we look at it, it has a new form. It reflects our own diversity, to some extent,
00:08:43 our own wiliness, our own imagination as humans. So to me, not a depressing book, because it is a
00:08:49 way to look directly at the face of the enemy. And I don't find that depressing. I find that
00:08:54 clarifying. And there are many, many high points in this journey. There's the invention of the great
00:08:59 surgeries that save tens of thousands, hundreds of thousands of lives around the world, the dramatic
00:09:05 advances against breast cancer, and most importantly, against some variants of leukemia, where the
00:09:11 mortality was 100% in 1950, and is 5 or 10% now. 95% change in mortality is a huge difference in
00:09:21 must rank as one of the great medical inventions of our time. So for me, far from a depressing book,
00:09:26 but to me, a clarifying book that tries to clarify why we're here today, where we're going, what happens
00:09:32 next, why we're not doing certain things, why we are doing certain things. So that's my impression
00:09:37 of what happened at the end of that book. When did the idea to write, as it's really referred to,
00:09:42 the biography of cancer, when did that idea come to you? Was it in your fellowship, in your training
00:09:46 at some point? Yeah, I was training, and it was a very simple moment. Actually, I remember a woman
00:09:50 who I was treating for cancer came to me, and I was giving her yet another trial of targeted therapy,
00:09:57 a new kind of therapy. And she finally sat down one afternoon, and she said, where are we going?
00:10:02 With all of this, why are we here? How did we get here? And she was, of course, asking it in a very
00:10:06 personal level, but you could take that question and make it a much, much larger question. Where are
00:10:12 we going in this battle against cancer? Why are we here today? What happens next? Why aren't we
00:10:17 elsewhere? How much of this is the wildness of this family of diseases? How much of this is the
00:10:22 capacity to use the greatest skills of our imagination against this illness? You know, in the 1930s,
00:10:30 1940s, 1950s, when you asked a child what the outer limit of their scientific imagination was,
00:10:37 they would say, I want to be a rocket scientist, and I want to send a rocket to the moon. By the
00:10:41 1950s, 60s, 70s, if you asked that same child what the outer limits of their scientific imagination
00:10:48 would bring to the world, they would say, I want to cure cancer. It began to define the limits of our
00:10:54 scientific prowess, or the limits of our imagination, a world without cancer. So there is a sense in which
00:11:02 this is such an elemental illness. So much of our culture is now defined through the lens of cancer.
00:11:09 And what was shocking as a fellow, when I started encountering cancer in a clinical sense,
00:11:14 what was shocking was that there was no such history, that it was all ad hoc, and we knew
00:11:19 little bits and pieces of it was like looking at the enemy through a patchwork quilt with little
00:11:24 holes in it. And the attempt here was to say, well, what is the full story? What does the story look like?
00:11:29 When did this start? Why did we end up here? What happens tomorrow? What happens way into the
00:11:34 future, a hundred years? What will cancer look like? And a lot of thought experiments go into
00:11:39 the book. So that's sort of the genesis of the book, and that's how it came about.
00:11:44 The research is also remarkable for a book like that. Anyone who's read it will appreciate. And again,
00:11:49 I think what's nice is this is one of those books where you can be an oncologist and read it and find
00:11:53 it staggering, and you can be someone who has lost a loved one to cancer but wouldn't know the
00:11:58 difference between a sarcoma and a leiomyosarcoma. It doesn't matter. The book resonates, which
00:12:03 obviously speaks to your ability to tell a story. And that's sort of, to me, what's mind-boggling
00:12:08 about that book is the way, and it's the same in the gene, by the way, is that you weave in and out
00:12:12 of a personal story and then something that's very dense scientifically. And on a personal level,
00:12:17 this is challenging because I'm in the process, as you know, of writing a book and doing a pretty
00:12:20 lousy job of it, I think. But it's this challenge of you want to be able to do the science
00:12:25 justice, but you need to be able to tell a story. So how does the scientist, Sid Mukherjee,
00:12:32 get along with the writer, Sid Mukherjee?
00:12:35 Well, I don't think they're two separate people. I think they're integrated into one person,
00:12:39 and that's very important. There are many people in my world, they wrote as a process of thinking.
00:12:47 Stephen Jay Gould comes to mind, not to draw a ludicrous comparison. Charles Darwin wrote to think.
00:12:52 Oliver Sacks wrote to think. I would suspect that Atul Gawande writes to think. I mean,
00:12:56 I know Atul. So the two people are fundamentally not different people in my brain. In order to do
00:13:04 the scientific work that I do, I need to think it through, often through the essays that I work on.
00:13:10 And they inspire in a kind of yin-yang or roundabout way, circular way, ways to find new ways of thinking
00:13:17 about the world, the cancer world. So there isn't a conflict. I don't feel a conflict.
00:13:21 The process is probably of interest. I mean, the process is that when I started writing Emperor,
00:13:26 I sort of made a personal vow or a strategy in writing that this was my first book. I'd never
00:13:32 written a book before. I wrote down some principles or tenets that I would follow,
00:13:37 and I've kept to them in every book since. The first one was that there will be no scientific
00:13:43 abstraction. At no place or point shall you go through five pages or three pages without there
00:13:50 being a human being in the middle of this. I'm a translational researcher. I'm a human scientist.
00:13:55 And that meant that I've made a personal promise that you wouldn't go through five pages without
00:14:00 understanding what the payoff of these pages that you've really worked your way through,
00:14:06 often as a reader, what the payoff is. So if you look carefully through that book,
00:14:11 every five to seven pages, the story comes alive in a human story,
00:14:15 in a scientific story, and in a scientist's story. They all intersect. And sometimes through
00:14:20 my stories, there are times that are tough. And I'm writing about the description, the first
00:14:25 cancer-causing genes, oncogenes, and their mutations. It's tough to say, well, what's the
00:14:31 human being? This is a laboratory experiment in which you sprinkle tens of thousands of bits of
00:14:37 genetic material onto cells and ask the question, which cells turn from normal to cancerous? And
00:14:42 that's the way you trap one of these cancer-causing oncogenes. What's the human story behind it? Well,
00:14:48 there are two stories. One story is quite lovely. It's the story of Bob Weinberg, the scientist who
00:14:53 you know, walking through Boston in a snowstorm and suddenly realizing, not in a one-to-one manner,
00:15:02 but this idea of sprinkling tens of thousands of genes onto pieces of genetic material onto cells,
00:15:08 like a snowstorm of genes, there's a kind of congruence to that story. It's not like Bob
00:15:12 Weinberg woke up one morning and saw a snowstorm and said, that's the experiment I should do. But
00:15:16 there's a kind of emotional congruence to the backstory of a scientist. But then the second story
00:15:24 that illustrates this point is to walk through a patient telescoping down, or rather microscoping
00:15:32 downwards from their outer cancer, a tumor, a lump, a mass that is about to kill them, a real patient
00:15:38 of mine, a man with lung cancer. And slowly in that same story of this man's illness, begin to
00:15:47 microscope down to the fact that he actually has in his cells this mutant gene that Bob Weinberg once
00:15:53 caught in this snowstorm of sprinkling genes on cells. And all of a sudden, this man's cancer
00:16:00 is sitting in a room in Boston, surrounded by his family, dying of metastatic lung cancer.
00:16:06 But at the heart, at the root of that lung cancer is that very same gene, that very same oncogene
00:16:12 that was discovered, described 10, 20 years before in a paper, in a kind of dry, abstract scientific
00:16:19 paper. And all of a sudden, that gene, the genetic material that can drive the growth of a normal
00:16:25 cell and make it malignant, make it metastatic, so metastatic, so malignant, that our best medicine,
00:16:31 our best minds can't stop the growth of this aberrant cell, all being driven, in part, by that
00:16:38 very same gene that was trapped 20 years ago in a laboratory experiment on rat cells. So all of a sudden,
00:16:45 this thing comes alive to you in a way that becomes consequential. If you didn't know the
00:16:50 identity of the gene, you would not understand why on earth this 70-year-old man in perfectly good
00:16:57 health is all of a sudden decimated by one or two or four or eight mutant genes in his cells that
00:17:05 suddenly take over and drive the growth of these cells. Anyway, that's one example that comes up over
00:17:09 and over again. That was the first tenet. That was the first tenet. So what was the second one?
00:17:13 There are many, so I'm not going to go through all the tenets. But the second one was that this book,
00:17:18 all these books, should be fundamentally readable by everyone. You talked about this already.
00:17:23 It should be like a kaleidoscope, that if you turn the book leftwards and you see it as an
00:17:29 oncologist, it's still interesting. The pattern changes. If you turn the book rightwards and say
00:17:34 you're an anthropologist, it still is interesting. If you turn the kaleidoscope upside down and shake it
00:17:41 and there's a new pattern that's formed, it's because you're reading the book now as a clinical
00:17:46 scientist. Or you're reading the book because your daughter has leukemia and you're the father
00:17:53 of a patient with leukemia. Or you're reading it because you yourself have been diagnosed with
00:17:58 breast cancer. Or your mother has. And all of a sudden, the kaleidoscope changes. But the point is
00:18:04 that the object remains the same. It's the same book, but you can read the book in various different
00:18:09 ways. You can come into it different ways. Often when I'm in, this sounds like a strange statement,
00:18:14 often when I come back from the wards, I reread my own writing to figure out sort of what was I
00:18:20 thinking then in 2008 when I wrote those sentences and how does that change now?
00:18:26 Has it really been 10 years?
00:18:27 It's been 10 years. So I should tell you that there will be a 10-year update to the emperor.
00:18:32 There'll be three additional chapters.
00:18:35 I assume one of them will be immunotherapy as an update.
00:18:37 That's right. So there are very broadly three sections that are updated. And I've thought about
00:18:42 it for a long time. So there'll be an updated section on prevention. There'll be an updated
00:18:47 section on early detection and an updated section on treatment. So that's the very broad three big
00:18:53 broad chapters. But in every chapter, there will be deeper dives into what's happened now since the
00:18:59 last 10 years and within the treatment section. And potentially within the prevention section,
00:19:03 there'll be a huge role of the immune system, which was not fully appreciated in 2010.
00:19:08 I thought that was the biggest distinction between the book when I read it and then the PBS special,
00:19:13 the Ken Burns special, which of course, again, we'll link to all of these things in the show notes
00:19:17 here. But one, you got to read the book. But two, I can't recommend enough the Ken Burns special.
00:19:23 They did an unbelievable job, I think, sharing your voice. And that was the biggest. I remember
00:19:28 watching it thinking, oh, wow, there's a big difference here. Because was it three installments
00:19:32 or five? I can't remember.
00:19:33 Three.
00:19:33 Yeah. The third installment felt like it was half immunotherapy.
00:19:36 It was half immunotherapy. Well, because part of the reason was that, again, this brings me to the
00:19:39 next tenet in the book or writing the book. The next tenet was that there is so much cancer research
00:19:45 in laboratories going on everywhere. And the tenet or the principle was that unless that research has
00:19:51 manifest itself in a human drug, in a human medicine, in a reconception of how we think about
00:19:59 preventing, treating, or detecting cancer, in a fundamental reconception of those ideas,
00:20:05 it won't get into the book. So tumor immunology, of course, had been around for a very long time,
00:20:10 Coley's toxins, famously, and other such efforts very, very early on. But in 2010, we were at the edge
00:20:17 of that moment in which we began to use tumor immunology in human beings as powerful medicines
00:20:25 to change the course of the disease. It was just the first trials that come out. And in fact,
00:20:30 the book was completed in 2009, and the first trials had not even come out then.
00:20:33 This is a little funny trivia story that I'd almost forgotten about this until somebody mentioned it
00:20:37 to me a year ago. I think the first real paper that I wrote as a fellow was on CTLA-4. It was
00:20:45 looking back at the series at NCI of patients who had been given CTLA-4 and responded, and this paper
00:20:51 basically identified the strong association between autoimmunity and their response to it.
00:20:55 Right.
00:20:56 Of course, this will be interesting later in our discussion because I want to, of course,
00:20:59 talk about James Allison. So we'll come back to that. But you're right. That was sort of when it
00:21:04 went from you had interleukin-2 that worked in maybe 10%, 15% of patients, but you couldn't predict
00:21:09 why. That was the bigger question. You didn't know why were some responding, and why were they only
00:21:13 responding with certain cancers, to where we are today, where it's really been a transformation
00:21:18 in the last 15 years?
00:21:20 Absolutely. And so when we started the film version of Emperor with Ken Burns, which I obviously was
00:21:25 very close, I worked very closely with Ken, I should say that the gene is also being made into
00:21:30 a film by Ken Burns.
00:21:31 Oh my God. It's like Christmas all over again.
00:21:34 It's almost completely shot. We're sort of moving towards editing phases and so forth.
00:21:38 When can people expect that?
00:21:39 Oh, it's already been scheduled. I think it's winter or fall 2019. So it's on the scale.
00:21:44 It's about a year from now.
00:21:45 Yeah, about a year from now. Yeah. We're working through footage and historical footage and archival
00:21:50 footage and so forth. But to wind backwards, the crucial piece that had been added since the book
00:21:55 was, of course, immunological therapy. So much of what the last episode was around this new
00:22:01 burgeoning field. I mean, in the first meeting that we had around the transformation of the book into
00:22:06 the documentary film, the first thing that was raised is what's changed? And the answer was very
00:22:11 obvious. What's changed is immunological therapy.
00:22:14 It might have been emphasized as much in the book, and I may have just missed it. Or it's possible you
00:22:18 also observed this as a change. But I believe it will factor into the 10th edition, which I can't
00:22:23 wait to get my hands on, is the role of obesity in cancer.
00:22:28 As if I recall, in the documentary, you said, look, this is now becoming basically the second
00:22:33 leading preventable cause of cancer after smoking, which was, again, I was aware of that at that
00:22:39 point in time because of the work that I'd been doing and sort of my little echo chamber. But I
00:22:43 thought, this is a PBS, this is not something that I think most people would appreciate. This is
00:22:48 becoming a first for many people to hear.
00:22:50 That's right. And the one thing that we should make clear is that every word in that PBS document
00:22:56 was vetted by some of the most important and thoughtful scientists and cancer biologists and
00:23:05 physicians and physician scientists and cancer advocates across the world. There's a backstory.
00:23:12 In other words, the script was vetted over and over again so that we wouldn't say things that were
00:23:17 misinforming the public or because this is documentaries for all time. Ken Burns's work
00:23:22 is evergreen. Hopefully, my work is evergreen. So it was very, very carefully vetted. And it was
00:23:28 quite clear by the time the documentary came out that the signals that we were picking up around
00:23:32 obesity and cancer were becoming extraordinarily clear for some cancers, obviously not for other
00:23:38 cancers. And the provocative statement that sits behind all of this is that really since the last
00:23:45 20-odd years, maybe even 30-odd years, we have been struggling, struggling to find preventable human
00:23:53 chemical carcinogens of substantial impact. Every word in that sentence is important. We have certainly
00:23:59 found new chemical carcinogens in humans, but often that affects small pockets of people who are exposed to
00:24:06 those carcinogens. We have found lots and lots of chemical carcinogens which have moderate to very small
00:24:13 impact if you look at populations overall. The bar might be smoking. So smoking is a good bar. This is a
00:24:20 smoking or tobacco smoke is a chemical carcinogen which is removable or preventable, and it has substantial
00:24:26 human impact across populations. Changing smoking behavior can change fundamentally the epidemiology of
00:24:32 cancers across nations. If that bar is smoking, we have struggled for the last 20-odd years to find things of that
00:24:39 magnitude and effect. The direct impact of that is when people come to me and they say, well, what do you do
00:24:46 to prevent cancer in yourself and your family? I have to sort of casually or not so casually admit that
00:24:52 not very much. I obviously don't smoke, but it's not like I'm eating goji berries or avoiding some
00:24:59 fundamental thing that everyone else is not in the know about because there aren't any. I mean, you know,
00:25:04 I'm obviously not exposing myself to these rare, unusual occupational cancer carcinogenic agents,
00:25:10 but I'm not doing something fundamentally changed that's different from you or anyone else to prevent
00:25:15 cancer. The exception to this rule of the 20-odd years of the hunt for chemical carcinogens is obesity.
00:25:24 Now, you and I can have a debate. Is obesity a chemical carcinogen? No, not in the traditional sense.
00:25:28 Is it even preventable? Maybe, but we have to think twice or three times about it. There's a role of
00:25:33 genetics and environment in all of this. And even do we think it's obesity per se or hyperinsulinemia
00:25:38 or any other endocrine? Exactly. First of all, is it an endocrine problem? Is it an inflammatory
00:25:42 problem? Or is it a metabolic problem? There are at least three horns. Yeah, obesity is such a
00:25:47 crude phenotype. That's right. To your point, has at least three, if not six underlying phenotypes
00:25:54 that each of which mechanistically would make a lot of sense for accelerating cancer.
00:25:59 This is an immunological phenomenon. The cytokines, the inflammatory, yeah, all of these things.
00:26:03 Going back to your general point that obesity was becoming identified more and more clearly
00:26:07 as one of the potential causes of cancer, or I should say strongly correlated with the
00:26:13 development of cancer so strongly that we think that there's a causal link based on all everything
00:26:18 that we know about epidemiology, some cancers, that we began to take this seriously. And we're
00:26:22 still taking it seriously. But as you're pointing out, there are several horns underneath that blanket
00:26:27 of obesity that we understand very crudely. And we have to figure out which of these is driving
00:26:31 the cancer risk. I would like to spend the next six hours discussing with you the tenets of writing
00:26:36 for selfish reasons. But instead, I'll punt that to a... We'll have dinner in a couple of weeks and
00:26:41 we'll finish that discussion. I want to talk about another book you wrote that doesn't get as much
00:26:45 attention, which is The Laws of Medicine. You wrote that after Emperor Before the Gene, correct?
00:26:49 That's right. So The Laws of Medicine has a very different mandate, as it were. And that's because
00:26:54 the book came out in association with TED. They had commissioned 10 books by 10 thinkers around the
00:27:01 world. And they asked me to write a book on that. And it's necessarily a small book. It's really a,
00:27:06 you know, the mandate was to write basically a 75-page book expanding on a single very,
00:27:11 very incisive idea. So that's The Laws of Medicine, yes.
00:27:14 If I got them correctly, the three laws are a strong intuition is much more powerful than a weak test.
00:27:19 How did you think of that? And what is the most important application of that law to the way you
00:27:24 think about medicine or specifically oncology today?
00:27:27 This, to me, is one of the great neglected ideas in medicine, perhaps one of the great
00:27:31 neglected ideas in the world. This idea initially comes from Thomas Bayes. This is a Bayesian idea.
00:27:37 Thomas Bayes was a cleric, but by evening he was a mathematician and an economist. And his work
00:27:45 leads to one of the most seminal and funny thought experiments that I've ever encountered,
00:27:48 which is the following. And I sometimes quiz my daughters with it, which is the following. This
00:27:53 is not Thomas Bayes' own example, but it arises out of Thomas Bayes' work. And he, one might imagine
00:27:58 going to a street fair and encountering a man who's tossing coins. And he tosses coins and your job is
00:28:06 to predict whether the next coin flip is going to be heads or tails. And so he tosses the coin 20 times
00:28:13 and all 20 times its tails. So then he turns to the crowd and he says, what's the next coin flip
00:28:20 going to be heads or tails? Now, the mathematician in the crowd, who's the professor of mathematics...
00:28:27 Says 50%. 0.76
00:28:28 Says 50%. And, you know, everyone says, absolutely right. But the child in the crowd says, no, no, you don't
00:28:34 understand. This is a stupid problem. It's the coin's rigged. The coin has only, it has two heads or two tails, 1.00
00:28:40 as the case may be. And the child's right. And what's important about that insight is that the
00:28:45 mathematician imagines the world, this in this case, this is not a stab at mathematicians in general,
00:28:51 but the professor of mathematics thinks of the world as having no history, as having no a priori's.
00:28:57 It's a world that's created de novo every time. The coin is flipped and its heads and tails equal
00:29:02 every time. But the child knows, and all humans know, that in fact, the world doesn't behave like
00:29:09 that. Everything has priors. And you need to understand those priors before you can understand
00:29:14 the posteriors. There's wisdom in that idea. And it took someone like Thomas Bayes to figure that out,
00:29:19 that most of our lives, we aren't living our lives like the crazy mathematician professor.
00:29:25 We are living our lives like the child. We're thinking to ourselves, what was the prior antecedent?
00:29:29 Imagine this is true for any corner of your life. The first question you ask yourself when you're
00:29:35 trying to solve a problem, trying to understand the cosmos, trying to understand something,
00:29:39 you ask yourself, what was the prior like? Did the sun set in the west last night? And how about the
00:29:45 night before? And maybe I don't need to create a formula to figure out whether the sun is going to
00:29:50 set on the west or the east tomorrow. It's because it's set on the west every time. There are obviously
00:29:54 loopholes and gaps to this kind of thinking. There are surprises that you can miss. So
00:29:58 Bayes' fundamental idea was that you can only interpret a test in the light of what that test
00:30:05 is predicted in the past. It's an extraordinarily important idea in the way we think about the universe,
00:30:10 that the past performance of a test tells you something, not everything, but tells you something
00:30:16 about the future performance of a test. And you can apply it to many, many things in the world. You
00:30:21 can apply it to any kind of thinking, economic thinking, climate change-oriented thinking, that
00:30:26 the past is a guide to the future, not only in a kind of loose way, but you're really using a real
00:30:33 stat weighted strongly by the past. And this, of course, applies to medicine. And it's a forgotten rule in
00:30:39 medicine. Although it does seem like one of the things that I've always felt physicians innately
00:30:43 do well without realizing it, which is the opposite of where I want to be, not to take the pot shots,
00:30:50 but I think where we do very poorly is in understanding asymmetric risk. So Nassim Taleb has
00:30:56 written a lot about asymmetric risk. And I think he's absolutely right to be critical of not just
00:31:01 physicians, but basically most people. So my argument is we are innately wired to be Bayesian.
00:31:07 Again, we are absolutely not innately wired to appreciate risk.
00:31:11 And both of these are important.
00:31:12 That's right. So one of them we have to hone so much more because I think it just doesn't
00:31:16 come naturally. I played a funny experiment, which you'll appreciate. I'll send you the
00:31:20 list and you'll have a field day with it. It's 20 questions and each one is a quantitative
00:31:26 question with an answer, but they're not obvious. You would never, it's not like how many,
00:31:30 you know, presidents were there or something where you might know the answer.
00:31:32 You ask the group, we're going to give you these 20 questions. I want you to answer each
00:31:37 question, not with a number, but with a 95% confidence interval.
00:31:41 You know the game?
00:31:42 No, I don't know the game. It's an interesting game.
00:31:43 Okay. So an interesting game. So at the end of 20 questions, if you've done it correctly,
00:31:47 you should have 19 out of 20 of those ranges. Correct. I've never met a person who can come 0.94
00:31:51 close. You almost without exception get like seven of the 20, right? You can't even contemplate
00:31:59 what that variability is. So the second law was that normals teach us rules, outliers teach us
00:32:06 laws. So this, of course, these were very carefully, I mean, I thought I've spent a lot of time
00:32:10 thinking about them. Of course, this is the anti-Bayesian law. This is the exactly what
00:32:14 you're talking about. This is the idea that simultaneously in the medical brain has to live
00:32:18 the idea that the Bayesian idea that when you hear hooves think horses, not zebras, famous medical
00:32:24 tenant. Hooves beats outside your window are likely to be horses. They're very unlikely
00:32:29 to be zebras. The second law is once in a while, they are zebras and you need tools. You need special
00:32:34 ideas, special tools to figure out what these outliers look like, who they are, how to find them,
00:32:41 and how to quickly find them so that you can identify them and triage them differently. So in some
00:32:48 ways, these two laws are yin-yang. They polarize against each other. And what's interesting about them
00:32:53 is that they both in medicine can both can be simultaneously true in the same way as our
00:32:59 assumption of a symmetric risk is simultaneously true with the idea that our understanding of the
00:33:05 of a world in the Bayesian way is helpful and important. So the second law is about how do you
00:33:10 identify outliers, how outliers tell us about the nature of normalcy, how they tell us about how
00:33:18 complex interactions can produce occasional far outsiders and how those outsiders really challenge
00:33:25 us to define what these interactions look like in real life. I mean, the simple example is, it's very,
00:33:31 very hard to figure out the genetics of any disease without finding the rare people who have the disease
00:33:39 as a consequence of a mutation. The classic example, of course, is that we would not have an idea
00:33:44 how to regulate our body or to prevent heart attacks. If we hadn't paid extraordinarily close
00:33:51 attention to a small family, small groups of families that had a mutation in the gene that controls
00:33:58 cholesterol metabolism, most people don't have this mutation because those families are quickly
00:34:02 extinguished, we think, because they die of heart attacks. They have all sorts of problems, they die of heart
00:34:07 attacks. But by paying extreme attention to this one family that has a mutation, they're rare,
00:34:12 scientists all of a sudden uncovered a whole cosmos in which we understand now cholesterol metabolism.
00:34:20 And because of that cholesterol metabolism, other scientists eventually developed the first statins.
00:34:24 So all of this, you know, the fact that hundreds of thousands of people in the world are taking
00:34:28 this medicine to prevent heart attacks, tracks back to a rare family where, because of a genetic
00:34:35 mutation, they had a very, very high risk of cardiac disease.
00:34:38 And of course, now we know there's a whole family of those people. There's at least 2,000 of those
00:34:42 mutations that produce that phenotype. And these natural experiments are actually a remarkable thing.
00:34:48 And of course, bringing it back to the gene, to now have a tool, a probe, to be able to explore that
00:34:54 is amazing. The third law, for every perfect or exceptional medical experiment, there is a human
00:35:01 bias that goes along with it.
00:35:02 Again, these are unique to medicine. And what's interesting about them is that they are unique,
00:35:06 to me, at least, though it's interesting, is that they're unique to the day-to-day practice of
00:35:10 medicine, but they apply for every, I think, they apply to every corner of life. You don't have to
00:35:16 be a doctor to realize that for every time we think of something, if you're really skeptical thinkers,
00:35:22 we have to think about the bias that comes intrinsically with that thought. In other words,
00:35:26 every single declarative claim about the universe that we're making must have necessarily a
00:35:34 declarative bias that comes with it. They're matched. If you want to be a scientist, if you
00:35:38 want to be a skeptic, your real job, aside from being creative and designing experiments,
00:35:44 is to find for every single declarative claim that you're making, the bias that drives sitting
00:35:51 like a little devil buried inside that declarative claim. Because I promise you, everyone has one.
00:35:57 Each one of these claims has one.
00:35:58 And Richard Feynman, who listeners of this podcast know, is one of my heroes. One of my
00:36:02 kids is named after him.
00:36:03 Is he named Feynman or Richard?
00:36:05 His middle name is Feynman.
00:36:06 I see.
00:36:06 Yeah. And my wife at first was like, why would we do that? But then once she had read,
00:36:10 surely you're joking, Mr. Feynman a couple of times, because she'd read it once before she
00:36:14 realized why. But Feynman said eloquently, right? The job in science is not to fool yourself,
00:36:19 and you're the easiest person to fool.
00:36:20 That's right.
00:36:21 So to your point, the only thing I would disagree with what you've said, Sid, is I don't think these
00:36:24 are unique to medicine. I think these are laws of science, and maybe laws of life on some dimension.
00:36:30 So the mandate here really was to use this book as a kind of springboard to challenge the way we
00:36:36 think about virtually all aspects of how we live. You're going to read an article in the New York
00:36:42 Times tomorrow that will make some claims about some politician somewhere in Oklahoma, or you're
00:36:50 going to read about an economic paper that is now being presented to the feds. And your job is to
00:36:55 be adequately skeptical about it and understand what are the priors? How do we explain this particular
00:37:02 fact based on the priors? Do the priors matter? To use a very topical example, does someone's past
00:37:08 behavior in college or in school, high school, tell us about how he or she is going to be a judicial
00:37:14 candidate?
00:37:15 Right. Or does their behavior under scrutiny in any way predict their behavior when no one's looking?
00:37:20 That's right. That's another question. The second question that you might ask here is,
00:37:24 again, it's an outlier question, right? Scrutiny versus not scrutiny. Do they become outliers to
00:37:30 themselves if they're scrutinized versus when they're not scrutinized? And the third question is,
00:37:35 when I read this story, what are my biases? Am I reading it because I'm a man? Am I reading it because
00:37:40 I have a particular experience in my own lifetime, myself, my sister, my daughter, my friend, my
00:37:47 colleague? Is that coloring the way that I read this particular story? So absolutely. And this
00:37:53 thinking goes on over and over again. These are circular processes. Do those biases have priors? Do
00:37:59 the priors have biases? And so forth. So you can use these. I mean, I certainly use these tools in
00:38:04 clinical practice.
00:38:05 Yeah. It's a beautiful, as you said, it's a very short book, but again, we'll certainly make sure
00:38:09 people have this link to it because I think it's a great way of teaching people how to think. And
00:38:15 that's, again, I just don't think we're innately wired for every facet of thinking. Now, going back
00:38:20 to your background in immunology, very recently, we had a very exciting, for those of us in this
00:38:25 space, very exciting Nobel Prize awarded. And it was, as we were discussing before we started
00:38:30 recording, it wasn't so much around immunotherapy, but a very specific element of it, which are the
00:38:34 development of checkpoint inhibitors. Two of them in particular were basically acknowledged
00:38:39 here, CTLA-4, which I mentioned earlier, and PD-1. Tell me why these are so exciting.
00:38:47 They're exciting for many reasons. They are exciting for, again, some history and some background. The
00:38:52 story, as it were, is exciting because if you ask the question in the 1990s, what's the relationship
00:38:59 between cancer and the immune system, you'd get a kind of diffuse answer. You'd get an
00:39:04 answer which could be very unclear because there were all sorts of complicated lines of
00:39:08 evidence. One line of evidence was that in patients with a complete collapse of the immune
00:39:13 system, such as patients with HIV, or complete collapse of at least one wing of the immune system.
00:39:20 They would get these cancers nobody else could get.
00:39:22 But what's interesting about them, and this is where the thought experiment, this is where the
00:39:25 brain cells start sort of ticking and wondering, they would typically get viral cancers, viruses that
00:39:31 would now get unleashed. We now know many of them. Viruses like human papillomavirus, they would get
00:39:37 cervical cancers, they would get anal cancers. So a lot of viral cancers, but patients with HIV did not
00:39:44 generally get lung cancer.
00:39:47 I never even thought of that, Sid. So we have enough data to know that they either at no greater
00:39:52 prevalence or even at a lower prevalence when you start to talk about, you know, for example,
00:39:56 lung cancer or GBM or pancreatic cancer. I never thought of that.
00:40:00 Yeah, it's very important. So the data are mixed because, of course, in the 1980s, they weren't
00:40:05 living long enough. So all that we know is that the first groups of cancers that cropped up in these
00:40:11 men and women were not lung cancers. They were not pancreatic cancer. So at the first pass with that
00:40:17 cut short data set, you might begin to imagine then if that's the case, the immune system completely
00:40:23 collapses, you only get a certain kind of cancer, then what is the possible role of the immune system
00:40:29 in cancer control? And if you were a nihilist, you might have given up in the 1990s and said,
00:40:35 well, you know, take the whole immune system away and nothing really happens even with this cut short
00:40:40 data set. So maybe there isn't such a complex interaction. Well, it turns out that people like
00:40:45 William Allison and his Japanese colleague did not put the immune system away. They put that data
00:40:51 aside, said, this goes back to the laws of medicine. They said, sure, it tells you a little
00:40:56 bit, but it doesn't tell you the full story. The full story turns out, there's one layer deeper.
00:41:01 The full story turns out that in people who don't have a collapse of the immune system, whose immune
00:41:06 system is otherwise intact, cancer cells, not all cancers, but some cancers make specific factors.
00:41:14 In fact, they evolve. The word make is the wrong word here. They evolve so that they put up specific
00:41:20 factors, put up specific signals that inactivate the immune system or that make the immune system
00:41:27 no longer able to kill or recognize the cancer cell. And the identification of these specific
00:41:33 pathways, these specific factors was what led to the Nobel Prize because in further work,
00:41:39 Jim Allison and again, his colleagues, this is a big wide field, showed that if you inactivate these
00:41:47 specific factors, if you drive nails through them using a variety of methods, then all of a sudden,
00:41:53 the cancers become revisible to the immune system and the immune system can attack and kill the cancer
00:41:58 cells. Now, why is it exciting? It's exciting for many reasons. First of all, it's important to realize
00:42:03 that not all cancers respond. We don't know why some do and some don't. Melanoma is highly responsive.
00:42:08 It's an immunologically engaged tumor. Is it because the melanoma has so many antigens that it will
00:42:13 suddenly be more recognizable? Is it because the skin is such a lymphoid organ? Is it the right
00:42:18 environment? We don't know all of these questions. The other thing to realize is that people have
00:42:22 responses and some people continue to respond. Some other people, sadly, will relapse and they'll go,
00:42:28 you know, the cancers will start growing back in the context of their re-educated immune system.
00:42:34 And that leads to the second question, which is what happens then? Is there a second pathway?
00:42:39 And this is an important idea, I think, that goes back to your first question, which is about whether
00:42:43 this is depressing or not. The important thing is once you drive a single stake through cancer's heart,
00:42:51 it's like placing the first crampon on a climb. You see, if there's no crampon that's placed on the
00:42:57 climb, you can't climb a mountain. It seems like a wall. It's a blank wall. And you don't know where
00:43:02 to go left or whether to go right or what to do. Once you plant that first crampon...
00:43:07 And it sticks.
00:43:08 And it sticks. You, all of a sudden, the whole face of the mountain becomes...
00:43:12 It's a different mountain now.
00:43:13 It's a different mountain now. Because now you can ask the question,
00:43:15 because the first crampon was planted in that particular place...
00:43:19 And it stuck.
00:43:19 And it stuck.
00:43:20 I have a new vantage point.
00:43:21 Exactly.
00:43:22 The perspective has changed.
00:43:23 That's right. And so this is the important piece to realize about cancer research and
00:43:27 perhaps about all research, is that the first crampon or the first stake through cancer's
00:43:31 heart is an incredibly important stake because then you can ask what I call linear questions.
00:43:37 Before that first one is placed, the questions are nonlinear. You don't know where to place
00:43:40 it. The whole map is open. Once you drive a stake through the first question, the world becomes
00:43:47 more linear. You can now ask the question, what's the mechanism of resistance to that?
00:43:51 And when you find that, what's the mechanism of resistance to that?
00:43:55 And so all of a sudden, the perspective is different because you've climbed through that
00:43:59 first. And that's usually where the Nobel Prizes are given. The Nobel Prizes are given often
00:44:04 for planting the first stake through the heart of a disease, through the heart of a problem.
00:44:09 And that's why this Nobel Prize is important. It's not, of course, as you're saying,
00:44:12 this does not encapsulate the field of tumor immunology in general. It's a wide field.
00:44:16 Our own lab does a whole bunch of work in tumor immunology, but we're on the shoulders of those
00:44:21 prior giants, as it were. And so that's the recognition that's been given here.
00:44:24 You said something that I think is so important and worth reiterating. There's also something about
00:44:29 immunology and immunotherapy that's quite interesting as far as planting that stake,
00:44:33 which is the durability of response. It is often the case that when you have an immunologic
00:44:37 remission, it is a durable remission. And it's not always the case, but it is much more likely the
00:44:41 case than when you say, for example, see a chemotherapeutic remission or even a surgical
00:44:46 remission. On a personal level, I have a very close friend who was diagnosed with colon cancer
00:44:51 10 years ago at a very young age. He might've been 40. And that was unusual in and of itself.
00:44:58 I remember talking. I went to the hospital when he had his colectomy, spoke with the surgeon after.
00:45:04 It sounded like a horrible case, huge tumor. The mesentery was full of nodes, which I assumed would be
00:45:10 positive. Every 26 nodes sampled all came back negative. My friend was adopted. We later realized
00:45:16 he had Lynch syndrome. Eight years later, he goes on to develop pancreatic adenocarcinoma,
00:45:21 unresectable. So it's encased the mesenteric vessels. He cannot have a Whipple procedure.
00:45:27 And as you know, and unfortunately many people listening to this will know, that is a death
00:45:31 sentence. It's a non-negotiable, you will not be alive in nine months. And he was put on an anti-PD-1
00:45:38 therapy because he happened to have, as you would know, patients with Lynch are going to be much
00:45:43 more likely to be susceptible to checkpoint inhibitors. Two years later, he's disease-free.
00:45:47 Just unbelievable stories. And I think your point is an elegant one that I'd never really
00:45:52 thought of before, which is focus less on the fact that we haven't solved the problem and more on the
00:45:57 fact that we have made a finite and real step towards establishing a new place, a new location
00:46:03 for which to view this disease.
00:46:04 That's right. So I describe this as taking a non-linear problem into a linear problem. Now,
00:46:10 of course, the answers are often not linear per se, but it gives you a route. I mean, we'll come back
00:46:14 to the metabolism study that we did with Lou Cantley. That is a great example of taking a non-linear
00:46:20 problem and converting into a linear problem. Now, I'll tell you about that in a second. But
00:46:24 anytime, this was the case with Gleevec too.
00:46:27 Let's tell people what Gleevec is. Yeah, it's a good story.
00:46:29 Gleevec is a good example of a drug where we learned to target a mutant cancer gene,
00:46:36 and it's actually the gene product. So in that case, the cancer, it's a blood cancer called
00:46:40 chronic myelogenous leukemia, was also a death sentence.
00:46:43 And also GI stromal tumors.
00:46:45 And GI stromal tumors, yeah. Chronic myelogenous leukemia was a death sentence. People had to
00:46:49 go through transplants. I've watched probably a dozen in the pre-Gleevec era, a dozen patients die
00:46:55 of chronic myelogenous leukemia or the complications of transplant. I trained briefly as a transplanter.
00:47:01 And then all of a sudden, through the work of many people, including Brian Drucker,
00:47:05 a drug was discovered. So before that, scientists figured out, based on very careful genetic analysis,
00:47:12 that the tumor was being driven by really the work of one gene. And the gene was called BCR-ABLE.
00:47:18 It's an oncogene. It's not found in normal cells, but found in these cancer cells.
00:47:22 And the product of that gene became like an engine, like a manic engine that was driving
00:47:28 these blood cells to go crazy and make more blood cells and proliferate and proliferate and
00:47:34 proliferate. And it was this engine gone wild inside a cell. And every time the cell asked the
00:47:39 question, should I divide, rather than looking at its normal state or nutrients, metabolic state,
00:47:44 et cetera, the only answer it would ever get was from this engine saying, yes, go ahead, make another
00:47:48 cell divide, et cetera, et cetera, et cetera. So this was identified, that the gene product was
00:47:54 identified, the protein product of the gene was identified. And then through an elaborate series
00:47:58 of experiments and circumstances, chemists found a way to actually jam the engine. One molecule,
00:48:04 human beings, we stitch this molecule together. It's a remarkable achievement. And once the engine
00:48:09 is jammed, it suddenly turns out that the disease goes into remission. This was one of the first
00:48:14 examples, there are others, of so-called targeted therapy, where you synthesize a chemical to jam
00:48:19 cancer's engines. In a cancer-specific way, it doesn't affect normal cells. But what's interesting
00:48:24 about that is that some people develop resistance because the engine, cancer cells evolve, and they find
00:48:31 a way of resisting. But that resistance, it becomes a linear problem. You figure out what the mechanism
00:48:37 of the resistance is, and you drive a second stake through cancer's heart. And when it becomes
00:48:41 resistant to that, you drive a third stake and so forth. So all of a sudden, the problem, which seemed
00:48:45 like a big blank rock, became a linear problem. So that goes back to another example of how that first
00:48:51 stake or the first crampon really helps with the problem. And now for immunotherapy, immunological
00:48:56 therapy, the roadmap is much clearer. Why do some tumors respond and why some don't respond? Is it a question
00:49:03 of the environment that the tumor is sitting in? Is it blood vessels? Is it tumor cells? Is it immune cells?
00:49:08 These are answerable questions. These are so-called linear questions. But the first big step here was
00:49:14 to define the problem. This is really a nice step off to exactly where I know we want to go, which is
00:49:19 we've got surgical oncologists, medical oncologists, radiation oncologists. In many ways, a subset now of
00:49:25 medical oncology is immunobased oncology. The work that you, Lou, and many others are now doing is
00:49:31 potentially another branch of oncology called metabolic oncology. So you're beyond gracious
00:49:39 in your suggesting I have even something to do with helping that evening turn into a, what sounds
00:49:44 like a very productive collaboration between you and Lou. And I'll be talking with Lou as well
00:49:48 in the next month, I'm sure. But let's talk a little bit about what came out of that collaboration
00:49:54 and certainly bring it back to Ben Hopkins' paper that was in nature, I believe.
00:49:59 It was in nature, yeah. Two weeks, three weeks ago, yeah.
00:50:00 Yeah. So let's talk a little bit about the question. What were you trying to understand?
00:50:04 So the question is, there's a very wide question and then there's a very narrow question.
00:50:09 The wide question is how does the body's metabolic state affect cancer? It's a very big question because
00:50:18 cancers, like all cells, are eating nutrients as well in order to grow. And the question,
00:50:23 therefore, is the cancer eating a different set of nutrients than normal cells? This work goes back
00:50:28 to famous work by Otto Warburg done in the early 1900s, 1920s, is that right? Yeah. Where Otto Warburg
00:50:36 was one of the first people to make the hypothesis that there's something fundamentally different
00:50:40 about, I mean, we won't go into great details, but it's fundamentally different in which the cancer
00:50:44 cells metabolize compared to normal cells. They use fundamentally different pathways to metabolize.
00:50:50 And if you could find a way to target these metabolic alterations in cancer cells, you'd find
00:50:55 an anti-cancer drug. So, but that question has been hanging around our field for a long time. And as
00:51:01 our understanding of normal metabolism has changed, we've begun to identify not just one, but dozens
00:51:07 of nutrient pathways that cancers use that may or may not be different from normal cells, maybe slightly
00:51:13 different from normal cells, maybe a lot different from normal cells. So that's one big question.
00:51:17 The second question, which is a slightly narrower question, is that when you give a drug, whatever
00:51:24 drug it might be, your favorite chemotherapy, your favorite drug, any drug, does it change
00:51:30 the metabolism of the cancer cell? And does it change the metabolism of the body? And could
00:51:36 this be a mechanism by which cancer cells become sensitive or resistant to chemotherapy? So these
00:51:40 are two related questions. Again, to reiterate, one question is, how is the cancer cell's metabolism
00:51:46 different from the normal cell in normal circumstances? And the second question is, how is a cancer cell's
00:51:52 metabolism deferred from a normal cell in the context of giving a drug?
00:51:56 Yeah. In other words, can a nutritional state be exploited and or a drug sensitivity be exploited
00:52:00 through a nutritional paradigm shift?
00:52:01 Exactly right. Those are the two questions. So we focused in this particular study, we actually
00:52:04 are interested in both. I'm interested in both. But we focused on the second question. And the second
00:52:09 question in this particular case was that there was a very promising group of medicines
00:52:13 that was being used in clinic. In fact, I had used them as a trialist. They had come really out of
00:52:19 Lou Cantley's path-defining work. He had defined the pathway or the signals that these medicines
00:52:25 attack. And there was an enormous amount of optimism because this was considered a fundamental pathway.
00:52:31 This is the beauty, by the way, of being in a place like New York or Boston. It's, you can talk
00:52:35 about someone doing this. I mean, Lou was in Boston when much of this work is done. He's now here in New
00:52:40 York. And you don't have to collaborate with a guy across the world. You can collaborate with
00:52:44 the guys on the Upper East Side instead of Chelsea.
00:52:46 That's right. So Lou's work over the last decades had been to define this pathway and ultimately led
00:52:53 to the formation or the creation of these new medicines. They're called PI3 kinase inhibitors,
00:52:57 and they go by fancy names like duvelacib and things like that. But anyway, when they came to clinic,
00:53:04 surprisingly, there were some responses. But there was a lot of resistance in patients that tumors
00:53:09 were resistant to the drugs and didn't respond. And that was a puzzle that Lou had come up with
00:53:13 in his own work. And then separately, seven miles uptown, I was scratching my head about the same
00:53:20 puzzle because I'd been using these same drugs in cancer patients and finding that patients became
00:53:26 resistant or were resistant to start. And so what was chalked out on a napkin that evening was we had
00:53:35 thought of lots of ways that these patients could become resistant. We had thought, oh,
00:53:39 maybe the tumor had a mutation.
00:53:41 Well, and there's one other point, I guess, to add just that we remember, but maybe it's worth
00:53:45 reiterating, is a lot of the patients that were on these began to develop phenotype. They looked
00:53:50 like they were diabetic.
00:53:51 Yeah. So that's the point that I was coming to in a second.
00:53:53 We didn't know if that meant that that was the source of the resistance.
00:53:56 That's right.
00:53:56 But was it true, true, and unrelated?
00:53:57 Yeah. The question was, was it true, true, and unrelated? I mean, you can think of many other
00:54:00 mechanisms of resistance. You can say the tumors got a mutation. You could say the host had some
00:54:05 problem. You could write down on the piece of paper a thousand ways. Those were the traditional
00:54:09 ways that one would explain resistance. The traditional ways of thinking about tumor resistance
00:54:13 is mutation. The host eats up the drug. The non-traditional way, and this is what the innovation
00:54:19 in the study was, that what if this diabetes that we were observing, the high levels of sugar and the
00:54:25 high levels of insulin, insulin being the most important piece of this, what if the drug was causing
00:54:30 diabetes separately from the tumor, given to normal people that the drug would cause diabetes,
00:54:35 in some people worse than others. And that diabetic phenotype, that diabetic state,
00:54:40 the hyperinsulinemic state, was being used or exploited by the tumor to essentially become
00:54:46 resistant to the drug. It's a little bit like, and the analogy that I drew, I remember,
00:54:51 on the napkin.
00:54:52 It's funny. I still remember the table we sat.
00:54:54 Yeah, I still remember the table. Yeah, exactly right. The drawing, so Lou and I were batting this
00:54:58 idea back and forth while you were eating nothing. And the idea was that, to me, it reminded me of
00:55:06 the famous story of the woodcutter who's sitting on a tree limb and chops off his own limb and falls
00:55:10 down. And I drew this picture, I remember, of the woodcutter on a tree limb because what happens is
00:55:16 that the body mounts an insulinemic response to the drug. That insulinemic response goes to the cancer
00:55:23 and starts feeding the cancer. And then the cancer becomes resistant. So you essentially undo all the
00:55:29 good that you've done with the drug by cutting off your own limb because of this intrinsic circuit.
00:55:34 And the long and short of it is that that's basically, in animal models, that happens to be
00:55:38 true. So we showed it using formal systems and formal methods that this insulinemia is a consequence
00:55:43 of the drug, has nothing to do with the tumor, has nothing to do with anything else. If you give the drug,
00:55:47 the drug goes into the liver and the pancreas and causes a sort of a pre-diabetic state that's often
00:55:53 worsened if you're already in a pre-diabetic state. This hyperinsulinemia is used then by the tumor
00:55:59 to become resistant even while the drug is present. It becomes a pathway by which the tumor becomes
00:56:04 resistant. And most interestingly, that you can paralyze this resistance by putting animals on a
00:56:11 ketogenic diet. So basically, there's never any sugar source to drive the insulin. You blunt the
00:56:17 insulin response so acutely that you can no longer get the insulin high. Again, this is not to be
00:56:22 confused with the idea that this is a sugar-feeding tumor idea. This is not a sugar-feeding tumor
00:56:27 paradigm. Because to be clear, on a ketogenic diet, your glucose levels might go down from normal,
00:56:34 but it's not an enormous reduction. Even in a complete fast, you'll still maintain at least
00:56:39 three millimolar of glucose. It's the insulin that becomes virtually unmeasurable.
00:56:43 That's right. So this is an insulin feeding the tumor question. And so I think the three points
00:56:48 that need to be made about the study to be very clear. First of all, it's an animal study. We're
00:56:53 now launching a human study that will launch in November with patients with lymphomas,
00:56:57 endometrial cancer, and breast cancer, particularly triple negative breast cancer I'm very keen on
00:57:02 studying. Because this is a cancer that has so few options. That's right. There are very,
00:57:05 few options. So that's the human study. The second point that is worthwhile making is that it's sort
00:57:10 of like, folks, don't try this at home. This is a very particular study with a very particular drug
00:57:16 on cancers combined with a diet. The study only worked when the drug and the diet were combined.
00:57:22 It does not mean that the ketogenic diet is going to prevent cancer. We don't know this. It's an open
00:57:26 question. We're actually studying that separately.
00:57:28 Yeah. And I want to talk just a little bit about that paper because that's, boy, I sure want everyone to
00:57:32 make sure they hear that loud and clear. Because few things upset me more than when I spend a little
00:57:37 too much time on Twitter and I come across people who seem to want to claim that if you're on a
00:57:40 ketogenic diet, you can't get cancer. Or if you have cancer, just go on a ketogenic diet. You're
00:57:44 going to be fine.
00:57:45 That's not, in fact, to be very clear.
00:57:47 Well, the study, in fact, demonstrated that that was not the case.
00:57:49 Not only that, the study also demonstrates that some cancer models, including leukemia,
00:57:53 is accelerated on the keto diet. In fact, we have a big follow-up study to try to figure out why
00:57:59 some cancers are accelerated by keto alone. But when you combine it with the drug,
00:58:03 they actually go back down into deep remission. The third point to make is that it seems to be
00:58:08 mutation agnostic. And by that, I mean, this is a very important idea, which is that 12 tumor
00:58:14 models responded. 12.
00:58:16 I was not aware that it was that high.
00:58:19 Yeah, 12. And actually, all 12 that we tested responded. Every one of them responded. And it didn't
00:58:25 matter what oncogenes you had or what tumor suppressor genes were mutated. They all responded.
00:58:30 Two different levels. Leukemias respond, then they relapse, at least in the models. Endometrial 0.58
00:58:36 cancers, we can't get them to grow. Pancreatic cancers respond extremely strongly. So it's another
00:58:40 example where you're not targeting, it seems, a mutation. This is not like Gleevec, in which you're
00:58:46 driving a stake into the engine of the cancer, or that engine.
00:58:49 Yeah, this is a much more global assault.
00:58:51 Yeah, it's a much more global assault. In fact, in some ways, it's parallel or akin to this
00:58:57 immunotherapy in the sense that the immune system doesn't care if you have RAS or doesn't seem to
00:59:02 care at the first approximation, whether you have a mutation in one gene or another gene, RAS or not
00:59:06 RAS. It will kill the tumor cells based on its characteristics of what it sees in the tumor.
00:59:12 Similarly here, the metabolism seems to be tumor-wide, but not single kinds of cancer-specific.
00:59:18 We don't know this to be the case. The 13th model that we try, maybe this was the one that
00:59:22 won't work. But this has generated a lot of excitement for this reason.
00:59:26 You know, I have a friend who has definitely HER2-new positive, maybe ER positive, PR negative,
00:59:31 but has stage four breast cancer, is in a PF3K inhibitor trial out of Dana-Farber,
00:59:35 has been on the trial for probably five years. She's the only survivor. Here's the interesting
00:59:39 thing. She's been on a ketogenic low-carbohydrate diet the entire time. 0.77
00:59:43 While she was taking inhibitor?
00:59:44 Yes.
00:59:45 Okay.
00:59:45 She's still on the inhibitor. 0.85
00:59:47 And so what's interesting is I've told Lou about her case because she's fastidious in this. And
00:59:53 she's able to get her hemoglobin A1c now under six, which for many of those patients is very
00:59:59 difficult.
00:59:59 Very hard to do, yeah.
01:00:00 When you, me, and Sid had lunch once about two years ago, this is the very first time you ever
01:00:05 showed me the data.
01:00:06 Yeah, that's right. We brought a computer.
01:00:08 We were at that Indian place or that Chinese place on 2nd Avenue.
01:00:11 That's right.
01:00:11 Yeah. And when you showed me those data, I just immediately thought of her.
01:00:15 So it's actually been on my list to introduce Lou because she doesn't live in New York,
01:00:19 but I want to bring her out and I want you guys to meet her because
01:00:23 the combination of this PI3K inhibitor and this dietary choice she's made,
01:00:27 going back to your second rule, right? She's the outlier that is giving you something to probe. 0.54
01:00:32 Yeah. We hopefully will have many such patients. I don't know. You know,
01:00:35 this is why we're running the study.
01:00:36 Sid, as you can probably imagine, I could spend another 12 hours speaking with you,
01:00:40 but I want to be respectful of your time. I know we're a little late in the day. We got a
01:00:44 later start than we wanted and you've got a long trip home and I want you to get to see your
01:00:48 family. The last question I want to ask you really is one that I need you to be a little
01:00:52 bit immodest with, which is how do you do what you do? I don't meet a lot of people that I look at
01:00:59 and realize that on every level of their life, they are better than me. You know, usually I meet
01:01:04 people and it's like, yeah, they're better at me at those three things, but I can do this one
01:01:07 thing better. And I'm sure I could think of something I do better than you, but it's-
01:01:11 Many things. You don't have my sense of balance.
01:01:14 I can probably shoot a bow and arrow better than you. But when I think about how you balance
01:01:19 the devotion you have to your patients, to your family, to your research, to your writing,
01:01:26 it humbles me. I don't know. Have you put any thought into that? The fact that you created these
01:01:30 tenets around writing is very interesting to me. It says that you weren't just a natural gifted guy
01:01:35 that fell out of the sky who figured out how to write. You know, you had to work at your craft.
01:01:40 So how do you work at this craft of just excellence in general?
01:01:43 The simple rules that I have is I'm a very question and project-driven person.
01:01:48 If I set projects, I'll usually fulfill them. Again, it's the same sort of crampon in the
01:01:53 mountain rule, which is that in order to write a book, you have to write the first line of the book.
01:01:57 And inevitably, that's not going to be the first line that survives. In order to do research,
01:02:01 you have to do one experiment. And inevitably, that experiment is going to not work out. You're
01:02:05 going to do 10, 15 iterations of it, etc. To me, the fundamental rule that works for me is just
01:02:12 to throw something at the world, the first line, the first experiment, the first idea,
01:02:16 and then keep at it. I keep at it over and over again. I come back to it. I come back to it over
01:02:22 and over again. And I keep asking questions. And then at some point of time, and that's another
01:02:27 moment of sensitivity, is to figure out when the work speaks back to you. The experiment starts
01:02:32 talking back to you. You have to be really open. Your ears have to be really open. And that's
01:02:37 really the skill of a scientist, I think. A scientist, I think, or even a writer, they have
01:02:42 really two skills that they mix together. The first one is the creative step, putting out the first
01:02:49 line, thinking of the idea. I'm going to write a biography of cancer. I'm going to write the history
01:02:54 of genetics, etc. But the second one is to be open enough to realize when the work starts speaking
01:03:00 back to you and let that happen. Let the experiment start talking back to you. Be skeptical of it.
01:03:05 Have a conversation with it. Those, I think, are the two skills that I sort of bring to my puzzle.
01:03:11 The rest of it is just like everyone else, trying to balance eating a meal versus, you know, writing
01:03:16 in two more lines, stopping, starting, sleeping, the usual.
01:03:21 Well, Sid, I don't expect this will be the last time we sit down and do this.
01:03:25 I hope not.
01:03:25 There's going to be a lot more stuff to talk about. I can't thank you enough. I consider you,
01:03:29 Lou, I mean, some of the other folks who talk about, I mean, real mentors of mine. And it's,
01:03:32 it's a, it's a privilege. It's a real privilege to call you a friend and to be able to sit down
01:03:37 with you and just get even the tiniest insight into your work. Thank you.
01:03:44 You can find all of this information and more at peteratiamd.com forward slash podcast.
01:03:49 There you'll find the show notes, readings, and links related to this episode.
01:03:53 You can also find my blog and the nerd safari at peteratiamd.com. What's a nerd safari, you ask?
01:03:59 Just click on the link at the top of the site to learn more. Maybe the simplest thing to do is to
01:04:04 sign up for my subjectively non-lame once a week email, where I'll update you on what I've been up
01:04:08 to, the most interesting papers I've read, and all things related to longevity, science, performance,
01:04:14 sleep, et cetera. On social, you can find me on Twitter, Instagram, and Facebook,
01:04:18 all with the ID peteratiamd, but usually Twitter is the best way to reach me to share your questions
01:04:23 and comments. Now for the obligatory disclaimer, this podcast is for general informational purposes
01:04:28 only and does not constitute the practice of medicine, nursing, or other professional health
01:04:32 care services, including the giving of medical advice. And note, no doctor-patient relationship
01:04:38 is formed. The use of this information and the materials linked to the podcast is at the user's
01:04:43 own risk. The content of this podcast is not intended to be a substitute for professional
01:04:47 medical advice, diagnoses, or treatment. Users should not disregard or delay in obtaining medical
01:04:53 advice for any medical condition they have and should seek the assistance of their health care
01:04:57 professionals for any such conditions. Lastly, and perhaps most importantly, I take conflicts of
01:05:03 interest very seriously. For all of my disclosures, the companies I invest in and or advise,
01:05:08 please visit peteratiamd.com forward slash about.